Global Market Analysis & Strategic Growth Patterns
In the current era of precision medicine and advanced cosmeceuticals, peptides have emerged as a cornerstone of biotechnological innovation. As a leading Peptides Manufacturer & Factory, Shaanxi Bieyouth Biotech Co., Ltd. observes a significant shift in the global industrial landscape. The global peptide therapeutics market is projected to exceed USD 50 billion by 2030, driven by the rising prevalence of metabolic disorders and the demand for highly targeted aesthetic treatments.
Moving beyond standard Solid-Phase Peptide Synthesis (SPPS), our factory integrates Liquid-Phase (LPPS) and hybrid methodologies to ensure 99%+ purity for complex long-chain peptides.
The explosion of GLP-1 agonists like Semaglutide and Tirzepatide has redefined the supply chain, requiring manufacturers to possess massive scale-up capabilities without compromising GMP standards.
Localized application scenarios in the US, EU, and Asia demand rapid fulfillment and rigorous regulatory documentation (DMF/FDA), which our facility provides as a standard protocol.
Established in 2018, Shaanxi Bieyouth Biotech Co., Ltd. has rapidly ascended to become a high-tier gold supplier in the global peptide and extract market. Our foundation is built on years of intensive foreign trade experience and a deep commitment to pharmaceutical-grade excellence.
Operating out of GMP-certified production facilities, we house two standardized workshops equipped with cutting-edge synthesis and extraction machinery. Our portfolio spans from therapeutic pharmaceutical raw materials to high-efficacy cosmetic peptides, reaching clients in the United States, United Kingdom, Canada, Russia, and Australia.
Research Breakthroughs
QC Control Levels
Capacity Leap (YoY)
Annual Tons Capability
Pioneering the Next Generation of Bio-active Peptides
The evolution of our factory follows a rigorous technical roadmap designed to maximize Information Gain for our partners. By 2026, we aim to transition 40% of our production to green enzymatic peptide synthesis, reducing chemical waste by 60% while increasing chiral purity.
Focusing on Peptide Drug Conjugates (PDCs) and macrocyclic peptides to overcome traditional bioavailability barriers.
Utilizing computational biology to predict peptide-receptor interactions, allowing us to offer unique OEM sequences for anti-aging and metabolic health.
Developing liposomal and micellar encapsulation technologies to enhance the stability of fragile peptides like Thymalfasin and Semaglutide.
Integrated Frameworks for Diverse Industrial Applications
Leveraging Matrixyl 3000, Argireline, and Copper Peptides to create high-performance serum bases for premium skincare brands. Our factory provides stabilized variants that withstand formulation pH fluctuations.
Supply of TB500 and BPC-157 at scale for research institutions and sports nutrition brands, ensuring rigorous batch-to-batch consistency and purity verification.
Specialized production lines for Semaglutide and Tirzepatide raw materials, compliant with international export standards and accompanied by full analytical dossiers.
Custom PSGAG and Chondroitin Sulfate solutions for pharmaceutical pet health products, addressing the growing market for companion animal longevity.
Participation in Shanghai International Cosmetics, Personal and Home care Raw Materials exhibition (PCHi), showcasing new peptide breakthroughs.
Obtained official FDA certification, solidifying our standing as a trusted global pharmaceutical raw material supplier.
Launch of the Institute of Biology; Expansion of foreign trade business to cover 50+ countries. Recognized as an "Integrity Enterprise".
Deep requirement communication regarding specifications and volume.
R&D development and prototype sampling for client verification.
GMP-standard bulk manufacturing with real-time QC monitoring.
Peptide quality is primarily determined by its purity (measured via HPLC), the absence of residual solvents (measured via GC), and the correct sequence verification (measured via Mass Spectrometry). At Bieyouth, we provide a full COA with every batch.
Yes. Our facility is designed for modular scaling. We handle initial milligram-scale custom synthesis for research and can scale to multi-kilogram and ton-level production for industrial applications using our 50,000-ton annual capacity framework.
We utilize advanced lyophilization (freeze-drying) techniques to convert peptides into stable powders. For temperature-sensitive shipments, we provide cold-chain logistics and specialized vacuum-sealed packaging to prevent degradation.
Absolutely. We assist our pharmaceutical partners with the necessary regulatory documentation, including DMF filings, to facilitate their clinical trial and market entry processes.
Bieyouth
